{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:58:16Z","timestamp":1781179096673,"version":"3.54.1"},"reference-count":36,"publisher":"Scientific Scholar","issue":"04","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["South Asian J Cancer"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:p>Background\u2003Acute lymphoblastic leukemia (ALL) is a common type of leukemia in children. The innovator pegylated L-asparaginase has several advantages over native L-asparaginase; however, its use in India is limited due to availability and cost. Therefore, a generic pegylated L-asparaginase can be considered as an alternative to the innovator molecule.<\/jats:p>\n                  <jats:p>Methods\u2003A retrospective study was conducted to assess the outcome (minimal residual disease [MRD]) and toxicity of a generic pegylated L-asparaginase (Hamsyl) at the end of induction therapy.<\/jats:p>\n                  <jats:p>Results\u2003Eighty-eight (80.7%) and 21 (19.3%) patients had received generic pegylated L-asparaginase and conventional asparaginase, respectively, as a part of their treatment protocol. Nearly 82% of patients had B-type ALL. Eight-one percent of children had a white blood cell count of fewer than 50,000\/mm3. At the end of induction, 80.7% (88) of children were minimal residual disease (MRD)-negative, and at the end of augmented consolidation therapy, 20.2% were MRD-negative. Ten percent of patients exhibited allergic reactions. Two children had pancreatitis, and one child had central venous thrombosis.<\/jats:p>\n                  <jats:p>Conclusion\u2003The generic pegylated L-asparaginase (Hamsyl) was effective and safe for use in pediatric ALL.<\/jats:p>","DOI":"10.1055\/s-0042-1759785","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T18:47:45Z","timestamp":1681152465000},"page":"371-377","source":"Crossref","is-referenced-by-count":2,"title":["Experience with Generic Pegylated L-asparaginase in Children with Acute Lymphoblastic Leukemia from a Tertiary Care Oncology Center in South India"],"prefix":"10.25259","volume":"12","author":[{"given":"Dhaarani","family":"Jayaraman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hemato-Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha M.","family":"Sneha","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hemato-Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gracelin","family":"Jeyarani","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hemato-Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8718-9376","authenticated-orcid":false,"given":"Alekhya","family":"Somayajula","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji Thiruvengadam","family":"Kothandam","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hemato-Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius Xavier","family":"Scott","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hemato-Oncology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gadekar","sequence":"additional","affiliation":[{"name":"Emcure Pharma, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"101679","DOI":"10.1016\/j.canep.2020.101679","article-title":"Childhood cancer in India","volume":"71","author":"S Ganguly","year":"2021","journal-title":"Cancer Epidemiol"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.phoj.2017.12.004","article-title":"Incidence of childhood leukemia and lymphoma in India","volume":"3","author":"S Asthana","year":"2018","journal-title":"Pediatr Hematol Oncol J"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/2278-330X.187591","article-title":"Acute leukemia in children: a review of the current Indian data","volume":"5","author":"R S Arora","year":"2016","journal-title":"South Asian J Cancer"},{"issue":"27","key":"ref5","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"C-H Pui","year":"2015","journal-title":"J Clin Oncol"},{"issue":"06","key":"ref6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1084\/jem.98.6.565","article-title":"Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. I. Course of transplanted cancers of various kinds in mice and rats given guinea pig serum, horse serum, or rabbit serum","volume":"98","author":"J G Kidd","year":"1953","journal-title":"J Exp Med"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.118.1.99","article-title":"Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance","volume":"118","author":"J D Broome","year":"1963","journal-title":"J Exp Med"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40265-019-01120-1","article-title":"Pegaspargase: A Review in Acute Lymphoblastic Leukaemia","volume":"79","author":"Y A Heo","year":"2019","journal-title":"Drugs"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/0976-500X.184769","article-title":"L-asparaginase in the treatment of patients with acute lymphoblastic leukemia","volume":"7","author":"R A Egler","year":"2016","journal-title":"J Pharmacol Pharmacother"},{"issue":"34","key":"ref10","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1200\/JCO.2014.55.5763","article-title":"Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4","volume":"32","author":"A L Angiolillo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/ijmpo.ijmpo_110_17","article-title":"Affordable and safe health care for all children: lessons learned from the use of peg-asparaginase in a developing country","volume":"38","author":"D Jayaraman","year":"2017","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/GO.20.00113","article-title":"Randomized, parallel group, open-label bioequivalence trial of intramuscular pegaspargase in patients with relapsed acute lymphoblastic leukemia","volume":"6","author":"M Nookala Krishnamurthy","year":"2020","journal-title":"JCO Glob Oncol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/08880018.2018.1538277","article-title":"Experience with generic pegylated L-asparaginase in children with acute lymphoblastic leukemia and monitoring of serum asparaginase activity","volume":"35","author":"C Vyas","year":"2018","journal-title":"Pediatr Hematol Oncol"},{"issue":"06","key":"ref17","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"V I Avramis","year":"2002","journal-title":"Blood"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/pbc.20684","article-title":"Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL)","volume":"47","author":"C S Kwok","year":"2006","journal-title":"Pediatr Blood Cancer"},{"issue":"02","key":"ref19","first-page":"175","article-title":"Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates","volume":"7","author":"A Abuchowski","year":"1984","journal-title":"Cancer Biochem Biophys"},{"issue":"09","key":"ref20","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","article-title":"Comparative pharmacokinetic studies of three asparaginase preparations","volume":"11","author":"B L Asselin","year":"1993","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/10428199309149129","article-title":"L-asparaginase and PEG asparaginase\u2013past, present, and future","volume":"10","author":"M J Keating","year":"1993","journal-title":"Leuk Lymphoma"},{"issue":"04","key":"ref22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","article-title":"Asparaginase-associated toxicity in children with acute lymphoblastic leukemia","volume":"57","author":"N Hijiya","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/MPH.0b013e3181483df1","article-title":"Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study","volume":"29","author":"P Wacker","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1200\/JCO.2000.18.7.1525","article-title":"Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia","volume":"18","author":"M H Woo","year":"2000","journal-title":"J Clin Oncol"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961","volume":"26","author":"E H Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"13","key":"ref26","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"W H Tong","year":"2014","journal-title":"Blood"},{"issue":"09","key":"ref27","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32A","author":"J Boos","year":"1996","journal-title":"Eur J Cancer"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3476(81)80955-9","article-title":"Risk factors for hyperglycemia in children with leukemia receiving L-asparaginase and prednisone","volume":"99","author":"C H Pui","year":"1981","journal-title":"J Pediatr"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"W Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","article-title":"FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL)","volume":"12","author":"P A Dinndorf","year":"2007","journal-title":"Oncologist"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjh.12016","article-title":"Asparaginase-associated pancreatitis in children","volume":"159","author":"R A Raja","year":"2012","journal-title":"Br J Haematol"},{"issue":"02","key":"ref32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pbc.22076","article-title":"Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis","volume":"53","author":"S L Kearney","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phoj.2018.03.001","article-title":"Retrospective post-marketing study on the use of bio-similar pegasparagase among acute lymphoblastic leukemia patients in India","volume":"3","author":"A Kamat","year":"2018","journal-title":"Pediatr Hematol Oncol J"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1365-2141.2007.06677.x","article-title":"Thrombosis and acute lymphoblastic leukaemia","volume":"138","author":"J H Payne","year":"2007","journal-title":"Br J Haematol"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1055\/s-2008-1076740","article-title":"L-asparaginase-induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children","volume":"39","author":"R Hourani","year":"2008","journal-title":"Neuropediatrics"},{"issue":"05","key":"ref36","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/pbc.24182","article-title":"Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia","volume":"59","author":"R Merryman","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"06","key":"ref37","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1182\/blood.V89.6.1886","article-title":"Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia","volume":"89","author":"S K Parsons","year":"1997","journal-title":"Blood"},{"issue":"05","key":"ref38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/08880018.2019.1634778","article-title":"PEGylated E. coli asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase Erwinia chrysanthemi availability","volume":"36","author":"A Verma","year":"2019","journal-title":"Pediatr Hematol Oncol"},{"issue":"09","key":"ref39","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","article-title":"Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study\u2013Dana-Farber Cancer Institute ALL Consortium Protocol 00-01","volume":"31","author":"L M Vrooman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13561-019-0257-3","article-title":"The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis","volume":"9","author":"X Hu","year":"2019","journal-title":"Health Econ Rev"}],"container-title":["South Asian Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1759785.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:12:48Z","timestamp":1781176368000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.sajc.org\/experience-with-generic-pegylated-l-asparaginase-in-children-with-acute-lymphoblastic-leukemia-from-a-tertiary-care-oncology-center-in-south-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":36,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2023,12,20]]},"published-print":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1759785","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2278-330X","2278-4306"],"issn-type":[{"value":"2278-330X","type":"print"},{"value":"2278-4306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,10]]}}}